
Vice Chair of the Department of Dermatology | University of California San Diego (UCSD) School of Medicine; Chief of Pediatric and Adolescent Dermatology | Rady Children’s Hospital San Diego, California, United States

Clinical Professor of Dermatology at the Icahn School of Medicine at Mount Sinai, NY; Clinical Assistant Professor of Dermatology & Pediatrics at Northwestern University Feinberg School of Medicine, Chicago, Illinois, US

Professor of Pediatrics and Medicine in the Division of Allergy and Immunology | University of California, San Diego; Director of the Eosinophilic Gastrointestinal Disorders Clinic | Rady Children’s Hospital–San Diego, California, United States

In this highlight video from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Mark Boguniewicz discusses the prevalence of food sensitization and food allergy in pediatric patients with AD, clarifying the difference between the two. Dr Boguniewicz also discusses the prevalence of other atopic comorbidities in children with AD

In this expert interview video focusing on topics from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Perla Lansang discusses how to identify pediatric patients with AD uncontrolled with topical therapies, considerations for the next step in care for these patients, and the potential benefits of early intervention with systemic treatment

In this clip from the April WCPD 2025 symposium, Dr Eulàlia Baselga discusses data identifying atopic dermatitis as the first diagnosed atopic disease and the start of the atopic march.

Dr. Amy Paller discusses the evolving concepts of early intervention and disease modification in AD and describes potential biomarkers of subclinical control at EADV 2025.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Amy Paller discusses the significant risk of developing other atopic diseases among infants with early-onset atopic dermatitis.
Dr. Ikuo Hirano and Profs. Arjan Bredenoord and Ingrid Terreehorst highlight the benefits of interdisciplinary care in EoE.

In this clip from the April WCPD 2025 symposium, Dr Amy Paller highlights CCL17 (TARC) as an important biomarker in AD.

In this exclusive KOL interview, Dr. Eric Simpson explores the cumulative, long-term impact of atopic dermatitis and highlights the potential benefits of initiating treatment early to help manage disease burden.

In this exclusive video interview, Dr Paula Luna discusses how disease modification can be defined in AD and how IgE may be used as a biomarker in AD.